12% Compliance Score at Supplement Maker Poses Imminent Threat to Vulnerable Groups

Healthcare practitioners and public health officials should be alarmed by the conditions revealed at Rehaan Healthcare’s facility: a 12% compliance score, pest infestations, and exposed waste in a unit producing supplements for children and the immunocompromised. This case is a stark reminder of the critical gaps in India’s supplement safety net that can directly jeopardize patient health.

The Food Safety and Standards Authority of India (FSSAI) has taken the decisive step of suspending the central licence of Rehaan Healthcare following a damning inspection of its health supplements and nutraceuticals manufacturing facility. The inspection revealed an egregious failure in compliance, with the facility scoring a mere 12% on the regulator’s overall assessment—a score indicative of “very serious failure and non-compliance of existing provisions.” This enforcement action, announced on July 24, 2026, marks one of the most significant regulatory crackdowns in the Indian nutraceuticals sector, underscoring the FSSAI’s renewed focus on high-risk food categories that directly impact public health.

“

The Food Safety and Standards Authority of India (FSSAI) has taken the decisive step of suspending the central licence of Rehaan Healthcare following a damning inspection of its health supplements and nutraceuticals manufacturing facility.

The inspection uncovered a litany of violations that painted a picture of total operational disregard for food safety standards. The premises were described as “extremely unhygienic and poorly organised,” with inspectors documenting sediments of filth and sludge accumulated beneath manufacturing tanks, disorganised storage of raw materials, and poor housekeeping that raised severe cross-contamination risks. Even more alarming were findings of spider webs, mould growth, flies, insects, and exposed food waste within the manufacturing area—conditions that are entirely unacceptable for any food facility, let alone one producing supplements intended for children and other vulnerable populations. Infrastructure deficiencies compounded the problems, with inadequate storage arrangements, insufficient workspace, poor ventilation and lighting, damaged structures, pest infestation, and the absence of a valid drinking water test report. Such a constellation of failures indicates not just isolated lapses but a systemic collapse of good manufacturing practices (GMP).

The FSSAI’s classification of health supplements and nutraceuticals as a “high-risk category” is particularly significant. These products, often consumed by children, pregnant women, the elderly, and individuals with compromised health, demand the highest levels of safety assurance. The unhygienic conditions and failure of food safety controls thus constituted an imminent threat to public health, prompting immediate licence suspension rather than a graduated enforcement approach. The regulator directed Rehaan Healthcare to cease all food business activities and manufacturing operations forthwith, with reinstatement contingent on rectifying all deficiencies and undergoing a verification by the competent authority. It also issued an explicit warning that any violation of the suspension order would trigger legal action, signalling a zero-tolerance stance that may set a precedent.

From a legal and regulatory standpoint, this enforcement action exemplifies the FSSAI’s expanding authority under the Food Safety and Standards Act, 2006, and its commitment to post-market surveillance. The authority has increasingly leveraged unannounced inspections and rigorous scoring to identify high-risk facilities, moving beyond mere punitive measures to a more proactive risk-based enforcement model. The 12% score is emblematic of a facility found completely wanting, and its public disclosure on social media platform X serves both as a deterrent and a transparency measure. The legal implications for Rehaan Healthcare extend beyond licence suspension; if follow-up inspections uncover continued non-compliance or if the company operates in defiance of the suspension, criminal prosecution under the Act could follow, potentially leading to fines and imprisonment for the responsible persons. Moreover, the public nature of the enforcement puts the company at risk of class-action lawsuits from consumers who may claim harm from products manufactured in such conditions.